p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.

[1]  P. Wollan,et al.  Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. , 1999, The American journal of surgical pathology.

[2]  C. Cordon-Cardo,et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.

[3]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[4]  L. Jin,et al.  DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. , 1998, The American journal of pathology.

[5]  V. Godfrey,et al.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.

[6]  M. Loda,et al.  Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. , 1998, The American journal of pathology.

[7]  I. Weinstein,et al.  Overexpression of p27Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. , 1998, Cancer research.

[8]  M. Kitagawa,et al.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. , 1998, The American journal of pathology.

[9]  Robert S. Kerbel,et al.  E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1 , 1998, The Journal of cell biology.

[10]  E. Campo,et al.  Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. , 1998, The American journal of pathology.

[11]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[12]  J. Richards,et al.  Hormone-induced proliferation and differentiation of granulosa cells: a coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1. , 1998, Molecular endocrinology.

[13]  E. Levin,et al.  Astrocyte Progression from G1 to S Phase of the Cell Cycle Depends upon Multiple Protein Interaction* , 1998, The Journal of Biological Chemistry.

[14]  R. Weinberg,et al.  The Expanding Role of Cell Cycle Regulators , 1998, Science.

[15]  James M. Roberts,et al.  The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury , 1998, Nature Medicine.

[16]  M. Loda,et al.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.

[17]  J. Cheville,et al.  Expression of p27kip1 in prostatic adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[18]  L. Jin,et al.  Expression of D-type cyclins in normal and neoplastic rat pituitary. , 1998, Endocrinology.

[19]  M. Kaplan,et al.  Stat Proteins Control Lymphocyte Proliferation by Regulating p27Kip1 Expression , 1998, Molecular and Cellular Biology.

[20]  S. Melmed,et al.  Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[21]  M. Loda,et al.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.

[22]  Y. Yatabe,et al.  p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. , 1998, Cancer research.

[23]  James M. Roberts,et al.  Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. , 1998, Molecular cell.

[24]  M. Roussel,et al.  Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[26]  G. Bradley,et al.  Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. , 1998, The American journal of pathology.

[27]  P. Wollan,et al.  Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[28]  R. Aguiar,et al.  Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours , 1998, Oncogene.

[29]  P. Seth,et al.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. , 1997, Cancer research.

[30]  M. Nakanishi,et al.  Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. , 1997, Biochemical and biophysical research communications.

[31]  R. Deshaies,et al.  A Complex of Cdc4p, Skp1p, and Cdc53p/Cullin Catalyzes Ubiquitination of the Phosphorylated CDK Inhibitor Sic1p , 1997, Cell.

[32]  Y. Doki,et al.  Deregulated expression of p27(Kip1) in human breast cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  N. Takuwa,et al.  Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts , 1997, Molecular and cellular biology.

[34]  T. Sano,et al.  Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[35]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[36]  A. Üren,et al.  Carboxyl-terminal Domain of p27Kip1 Activates CDC2* , 1997, The Journal of Biological Chemistry.

[37]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[38]  B. Scheithauer,et al.  Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. , 1997, The American journal of pathology.

[39]  K. Post,et al.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation , 1997, Molecular carcinogenesis.

[40]  M. Kerin.  Cancer principles and practice of oncology , 1997 .

[41]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[42]  M. Piris,et al.  Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. , 1997, The American journal of pathology.

[43]  S. Shousha,et al.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Melmed,et al.  Genetic basis of endocrine disease: pituitary tumor pathogenesis. , 1997, The Journal of clinical endocrinology and metabolism.

[45]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[46]  S. Melmed,et al.  Pituitary Tumor Pathogenesis1 , 1997 .

[47]  P. Heikkilä,et al.  Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[48]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[49]  K. Hruska,et al.  Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. , 1997, Endocrinology.

[50]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[51]  M. Pagano,et al.  Enhanced Ribosomal Association of p27Kip1 mRNA Is a Mechanism Contributing to Accumulation during Growth Arrest* , 1997, The Journal of Biological Chemistry.

[52]  M. Pagano,et al.  Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation , 1997, Leukemia.

[53]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[54]  P. Steeg,et al.  Cancer prognostics: Past, present and p27 , 1997, Nature Medicine.

[55]  L. Jin,et al.  Aberrant p27kip1 expression in endocrine and other tumors. , 1997, The American journal of pathology.

[56]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[57]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[58]  M. Raff,et al.  Accumulation of the cyclin‐dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation , 1997, The EMBO journal.

[59]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[60]  B. Amati,et al.  Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc. , 1996, The EMBO journal.

[61]  R. Kerbel,et al.  Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.

[62]  T. Hunt,et al.  The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. , 1996, The EMBO journal.

[63]  Philip D. Jeffrey,et al.  Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.

[64]  L. Jin,et al.  Transforming growth factor-beta and p27 expression in pituitary cells. , 1996, Endocrinology.

[65]  K. Post,et al.  Frequent loss of the P16INK4a gene product in human pituitary tumors. , 1996, Cancer research.

[66]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[67]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[68]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[69]  H. Koeffler,et al.  p27/Kip1 mutation found in breast cancer. , 1996, Cancer research.

[70]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[71]  M. Shuford,et al.  Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. , 1996, The Journal of clinical investigation.

[72]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[73]  T. Hunter,et al.  Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells , 1996, Nature.

[74]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[75]  B. Clurman,et al.  Cell cycle and cancer. , 1995, Journal of the National Cancer Institute.

[76]  M. Tomonaga,et al.  Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. , 1995, Blood.

[77]  T. Hunter,et al.  Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. , 1995, Molecular biology of the cell.

[78]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[79]  X. Bertagna,et al.  Recent advances in the pathogenesis of adrenocortical tumours. , 1995, European journal of endocrinology.

[80]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[81]  J. Roth,et al.  Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. , 1995, Cancer research.

[82]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[83]  S. Nagataki,et al.  Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. , 1995, Cancer research.

[84]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[85]  D N Shapiro,et al.  Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4 , 1995, Molecular and cellular biology.

[86]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[87]  A. Goldberg.  Functions of the proteasome: the lysis at the end of the tunnel. , 1995, Science.

[88]  A. Kamb,et al.  Cell-cycle regulators and cancer. , 1995, Trends in genetics : TIG.

[89]  M. J. Ravitz,et al.  Transforming growth factor beta-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T1/2 mouse fibroblasts. , 1995, Cancer research.

[90]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[91]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[92]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[93]  G. Hannon,et al.  Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD , 1995, Science.

[94]  J. Massagué,et al.  Mammalian antiproliferative signals and their targets. , 1995, Current opinion in genetics & development.

[95]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[96]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[97]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[98]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[99]  J. Massagué,et al.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1 ) of cyclin-dependent kinase 4 activation , 1994, Cell.

[100]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[101]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[102]  J. Roberts,et al.  Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes , 1994, Molecular and cellular biology.

[103]  L. Hengst,et al.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells , 1994, Molecular and cellular biology.

[104]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[105]  A. Arnold.  Molecular mechanisms of parathyroid neoplasia. , 1994, Endocrinology and metabolism clinics of North America.

[106]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[107]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[108]  A. Arnold.  Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia. , 1993, The Journal of clinical endocrinology and metabolism.

[109]  James M. Roberts,et al.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.

[110]  J. Fagin.  Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. , 1992, The Journal of clinical endocrinology and metabolism.

[111]  James M. Roberts,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle , 1992 .

[112]  I. Doniach.  Functional Endocrine Pathology , 1991 .

[113]  R. Eddy,et al.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. , 1989, The Journal of clinical investigation.

[114]  Craig R Moores,et al.  H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors , 1984, The Journal of experimental medicine.

[115]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[116]  B. Wold,et al.  p27Kip1 is expressed transiently in developing myotomes and enhances myogenesis. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[117]  G. Cattoretti,et al.  Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.

[118]  R. Lloyd,et al.  TGFβ, TGFβ receptors, Ki-67, and p27Kip1 expression in papillary thyroid carcinomas , 1997 .

[119]  W. Farrell,et al.  Tumour suppressor genes in the pathogenesis of human pituitary tumours. , 1997, Hormone research.

[120]  C. Larsson,et al.  Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. , 1996, Thyroid : official journal of the American Thyroid Association.

[121]  M. Hochstrasser.  Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. , 1995, Current opinion in cell biology.

[122]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.

[123]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[124]  D. Rubin,et al.  The proteasome : a protein-degrading organelle ? , 2022 .